semaglutide soul Oral semaglutide lowers risk of heart failure events - SOULtrial summary Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events The SOUL Trial: A Deep Dive into Oral Semaglutide's Cardiovascular Benefits

Soultrialsemaglutidestopped The SOUL (Semaglutide Cardiovascular Outcomes) trial has emerged as a pivotal study in understanding the cardiovascular implications of semaglutide, particularly oral semaglutide. This comprehensive cardiovascular outcomes trial (CVOT) investigated the efficacy of once-daily oral semaglutide in individuals with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both. The SOUL trial provides robust evidence supporting the cardioprotective effects of this GLP-1 receptor agonist.

Understanding the SOUL Trial Design and Objectives

The SOUL trial was a large-scale, randomized, double-blind, parallel-group, placebo-controlled studyOral semaglutide and cardiovascular outcomes by .... It enrolled 9,650 participants, who were administered either oral semaglutide at a dose of 14 mg once daily or a placebo, in addition to their standard of care. The primary objective was to assess the impact of oral semaglutide on major adverse cardiovascular events (MACE), which typically include a composite of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke.Oral Semaglutide and Heart Failure Outcomes in Persons ... Beyond the primary endpoint, the trial also explored secondary endpoints related to heart failure, kidney outcomes, and quality of life作者：CR Schwarz·2025—Large injectable CVOTs have demonstrated robust cardioprotection, and theSOULtrial now shows a 14% reduction in major adverse cardiovascular .... The design of the SOUL study, as a dedicated CVOT, ensures rigorous evaluation of cardiovascular risk reduction.2025年12月4日—In this prespecified analysis of theSOULtrial, oralsemaglutideadded to standard of care numerically reduced the number of major kidney ...

Key Findings: Cardiovascular Risk Reduction with Oral Semaglutide

The SOUL trial delivered compelling results, demonstrating that oral semaglutide significantly reduced the risk of major adverse cardiovascular events. In a prespecified analysis, oral semaglutide was associated with a notable 14% reduction in MACE compared to placebo over an average follow-up period of nearly four years. This significant outcome confirms semaglutide's role as a potent agent for managing cardiovascular risk in high-risk diabetic populations. Further analyses also indicated that oral semaglutide reduced major adverse cardiovascular event outcomes in type 2 diabetes patients and that the oral semaglutide demonstrated a 14% reduction in major adverse cardiovascular events in people aged 50 years or older with type 2 diabetesImpact of Oral Semaglutide on Kidney Outcomes in People ....

The cardiovascular benefits were consistent across various baseline categories, including BMI and A1C levels, suggesting broad applicabilityOral semaglutide confirms cardioprotection in type 2 diabetes. Moreover, oral semaglutide not only lowered MACE but also demonstrated a reduction in heart failure events.作者：CR Schwarz·2025—Large injectable CVOTs have demonstrated robust cardioprotection, and theSOULtrial now shows a 14% reduction in major adverse cardiovascular ... Specifically, oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes, with a reduction in heart failure-related hospitalizations observed.

Beyond Cardiovascular and Renal Endpoints

The impact of oral semaglutide extends beyond just cardiovascular and renal health. The SOUL trial revealed that semaglutide also significantly improved walking distance, symptoms, and quality of life in participants with symptomatic peripheral artery disease (PAD). This improvement in functional capacity and symptomatic relief highlights the multifaceted benefits of the drug. A prespecified analysis of the SOUL trial also showed that oral semaglutide added to standard of care numerically reduced the number of major kidney events, further underscoring its benefit in managing complications associated with diabetes.

The Evolving Landscape of Semaglutide Therapy

The findings from the SOUL trial build upon existing data from other significant trials, such as the SELECT study, which focused on subcutaneous semaglutide. Semaglutide, a GLP-1 analogue, has consistently proven its efficacy and safety in treating patients with type 2 diabetes and high cardiovascular risk across various formulations.2024年10月23日—An oral formulation ofsemaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone. The SOUL trial specifically validates the cardiovascular benefits of the oral formulation, positioning it as a crucial therapeutic option. The SOUL trial summary indicates a strong performance for oral semaglutideThe findings from this prespecified analysis of the SOUL trial suggest thatoral semaglutide reduces major adverse cardiovascular event outcomesin type 2 ....

Oral semaglutide's role as a dual-action cardiometabolic agent is further solidified by these results作者：DK McGuire·2023·被引用次数：166—SOUL is a randomized, double-blind, parallel-group, placebo-controlled CV outcomes trialcomparing oral semaglutide (14 mg once daily) with placebo.. Its well-established safety profile and durable efficacy make it a valuable tool in the management of patients with high cardiovascular risk, offering a convenient once-daily oral administration作者：R Pop-Busui—Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events(MACE; comprising CV death, nonfatal myocardial infarction, or .... The Results of SOUL Trial with Oral Semaglutide provide a clear picture of its therapeutic potential. The SOUL trial NEJM publication is anticipated to provide in-depth data for the medical community.

In conclusion, the SOUL (Semaglutide Cardiovascular Outcomes) trial has provided critical evidence supporting the once-daily oral semaglutide regimen for individuals with type 2 diabetes and high cardiovascular risk. The significant reduction in MACE, favorable impact on heart failure and kidney outcomes, and demonstrated improvements in quality of life underscore the comprehensive benefits of this medication. The SOUL trial confirms oral semaglutide's position as a cornerstone in the management of cardiovascular complications in this patient population.